BPMC

Blueprint Medicines Corporation (BPMC) | Rumor.io

Blueprint Medicines

BPMC

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)93%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BPMC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jul 7

Blueprint Medicines Corporation ($BPMC) has an upcoming HSR expiration on Wednesday, with action in 125 puts across multiple expirations.
The efficacy comparison between $BPMC's Ayvakit and Cogent Biosciences' ($COGT) Beztyn remains unclear, with some arguing that $COGT's TSS improvement is inflated.
$BPMC's Ayvakit may have a competitive advantage over $COGT's Beztyn, with some analysts suggesting that $BPMC's pricing strategy has contributed to its market position.

Generated by AI

Sentiment

Of the messages about BPMC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	91.78%	96.89% +7.98
Bearish	—	—	8.22%	3.11% -7.98

Bullish· Jun 3

$BPMC's acquisition by $SNY for $9.5 billion represents a 26.09% surge in shares, with a market cap of $8.25B.
Blueprint Medicines' stock has shown strong momentum, with a 46.51% increase in 2025 and a 25.42% year-over-year gain.
The company's pipeline and future prospects have significant value, with a potential $2B deal for Novavax's combination therapy contributing to its overall valuation.

Bearish· Apr 28

The company's lead drug failed a GIST study, causing shares to drop 15% premarket.
The asset's recent performance has been disappointing, with a -20.1% decrease in share price.
The Voyager trial for the company's drug resulted in a significant decline, with some users hoping for a 75% drop in the asset's value.

Generated by AI

Topics

Of the messages about BPMC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	0%	0%	0%
Macro	—	0%	0%	0%
Earnings	—	0%	0%	0%
Controversies	—	0%	0%	0%
Announcements	—	100%	100%	97.8%
Analysts	—	0%	0%	2.2%

Earnings· May 2

Blueprint Medicines Corporation ($BPMC) reported a loss of $1.29 per share, missing consensus estimates by $0.23.
The company will host a Q1 earnings call today at 8:30 AM Eastern, which can be streamed live or replayed later.
$BPMC's earnings results missed expectations, with a loss of $1.29 per share and revenue of $0.95 million.

Analysts· Nov 2

Analysts have lowered their price targets for Blueprint Medicines Corporation, with Barclays reducing its target to $58, Morgan Stanley to $75, and SVB Leerink to $52.
Wedbush analyst Liana Moussatos maintains an Outperform rating with a lower price target of $106, while HC Wainwright analyst Andrew Fein lowers his Buy rating target to $70.
Oppenheimer Holdings Inc. has downgraded Blueprint Medicines to Market Perform, and analyst Matthew Biegler has also downgraded the company from Outperform to Perform.

Announcements· Jun 2

Sanofi is acquiring Blueprint Medicines for $129 per share in cash, valuing the company at approximately $9.1 billion upfront.
The deal includes a contingent value right (CVR) that could increase the total value to $9.5 billion, with potential milestone payments of $2 and $4 per CVR.
The acquisition is expected to be completed in Q3 2025 and is seen as a strategic step forward for Sanofi in its rare and immunology portfolios.

Generated by AI

Community

Of the messages about BPMC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	99.05%	75.53%
Newcomers	—	0%	0.95%	24.47%

Regulars· Jun 2

Sanofi is acquiring Blueprint Medicines for $9.1 billion in cash, with a price of $129 per share.
The acquisition will expand Sanofi's portfolio in rare immunological diseases and add an early-stage pipeline in immunology.
Sanofi's purchase price is a premium to the market value of Blueprint Medicines, with the company's stock removed from some investors' watch lists.

Newcomers· Jun 4

Newcomers are predicting a short-term negative trend in the stock price of Blueprint Medicines Corporation.
The company is trending due to its acquisition by Sanofi, with some users questioning the reason behind the trend.
The acquisition price is up to $9.5 billion, with Sanofi acquiring Blueprint to expand its cell development capabilities.

Generated by AI

News

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

VANCOUVER, British Columbia, July 06, 2026--AbCellera Appoints Dr. Lynn Seely to its Board of Directors

2mo agoYahoo Finance

Also Discussed

Investors talking about BPMC also mention

#	Name	Attention
1	Immunocore Holdings plc ADRIMCR	0%0
2	SWTX - SpringWorks Therapeutics, Inc.	——
3	Biohaven Ltd.BHVN	0%-0.01
4	Relay Therapeutics Inc.RLAY	0%new
5	Agios Pharmaceuticals, Inc.AGIO	0%0
6	IDEAYA Biosciences Inc.IDYA	0%-0.01
7	DCPH - Deciphera Pharmaceuticals, Inc.	——
8	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
9	Alnylam Pharmaceuticals, Inc.ALNY	0%0
10	FGEN - FibroGen, Inc.	——